Sam Brusco, Associate Editor01.13.23
Inari Medical, a company focused on transforming lives of those suffering from venous and other diseases, announced the first patient was enrolled in its DEFIANCE trial to compare clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with its ClotTriever system versus anticoagulation only.
The trial is led by principal investigators: Dr. Xhorlina Marko, Interventional Radiologist at Beaumont Health; Dr. Steven Abramowitz, Chair of Vascular Surgery at MedStar Health; and Professor Stephen Black, MD, consultant vascular surgeon, Guy's and St. Thomas' Hospital, London.
The first DEFIANCE patient was enrolled by Dr. Abdullah Shaikh, Interventional Radiologist at Allegheny Health Network. DEFIANCE will enroll 300 DVT patients at up to 60 centers globally. The trial is Inari’s second RCT, enrolling in parallel to its PEERLESS pulmonary embolism trial.
“We’re thrilled to enroll the first patient and officially kick off this important clinical trial,” Dr. Shaikh told the press. “ClotTriever is fundamentally different than other DVT treatments. This trial is designed to produce definitive evidence to change standard of care.”
“DEFIANCE is an important step forward and will answer critical questions about how we manage DVT patients,” said Dr. Steven Abramowitz. “Prior RCTs have focused on thrombolytic-based interventions, which have known downsides and limited effectiveness. This ClotTriever RCT is the first to compare lytic-free thrombectomy to anticoagulation for DVT.”
“With six major clinical studies, including two ongoing RCTs, Inari is wholly committed to VTE patients and producing definitive evidence to support our technologies,” said Dr. Thomas Tu, Inari’s chief medical officer. “None of this is possible without the collaboration and dedication of our clinical trial investigators who continually push the field forward in the name of better patient outcomes.”
The trial is led by principal investigators: Dr. Xhorlina Marko, Interventional Radiologist at Beaumont Health; Dr. Steven Abramowitz, Chair of Vascular Surgery at MedStar Health; and Professor Stephen Black, MD, consultant vascular surgeon, Guy's and St. Thomas' Hospital, London.
The first DEFIANCE patient was enrolled by Dr. Abdullah Shaikh, Interventional Radiologist at Allegheny Health Network. DEFIANCE will enroll 300 DVT patients at up to 60 centers globally. The trial is Inari’s second RCT, enrolling in parallel to its PEERLESS pulmonary embolism trial.
“We’re thrilled to enroll the first patient and officially kick off this important clinical trial,” Dr. Shaikh told the press. “ClotTriever is fundamentally different than other DVT treatments. This trial is designed to produce definitive evidence to change standard of care.”
“DEFIANCE is an important step forward and will answer critical questions about how we manage DVT patients,” said Dr. Steven Abramowitz. “Prior RCTs have focused on thrombolytic-based interventions, which have known downsides and limited effectiveness. This ClotTriever RCT is the first to compare lytic-free thrombectomy to anticoagulation for DVT.”
“With six major clinical studies, including two ongoing RCTs, Inari is wholly committed to VTE patients and producing definitive evidence to support our technologies,” said Dr. Thomas Tu, Inari’s chief medical officer. “None of this is possible without the collaboration and dedication of our clinical trial investigators who continually push the field forward in the name of better patient outcomes.”